Pipeline
| Program | Indication | Discovery | Preclinical | IND | Ph l | |
|---|---|---|---|---|---|---|
| ADC |
PLB-002 |
Ovarian Cancer,Lung Cancer |
|
2025 Q4(China) 2026 Q1(outside of China) |
||
|
PLB-003 |
Solid tumors |
|
||||
|
PLB-004 |
Solid tumors |
|
||||
|
ADC (dualpayloads) |
PLB-001 |
Lung cancer |
|
|||
|
PLB-005 |
Solid tumors |
|
||||
|
DAC |
PLB-006 |
TBD |
|
|||
| Bispecifc ADC | PLB-007 | Solid tumors |
|
|||
| PLB-008 | Solid tumors |
|
||||
Add:
Building 4, Suhua Science Park , No.208 Tongyuan Road, Suzhou Industrial Park
Follow Us
©2022 PrimeLink BioTherapeutics Powered by：CEglobal